TAMPERE, Finland, Feb. 13, 2026 /PRNewswire/ -- This company announcement is a summary of Bioretec Ltd's financial statements bulletin for January–December 2025. The complete financial statements bulletin with tables is attached to this release as a pdf file and available at the company's web pages at https://investors.bioretec.com/en/reports_and_presentations The financial statements bulletin is unaudited.
July–December 2025 in brief
Net sales amounted to EUR 1,448 thousand (6–12/2024: EUR 2,482 thousand)
Sales margin was EUR 1,006 (1,770) thousand, or 69.5% (71.3%) of net sales
EBITDA was EUR -3,919 (-2,189) thousand
The result for the reporting period amounted to EUR -3,855 (-2,730) thousand
On December 16, Bioretec updated its strategy for 2026–2028 and provided new financial targets for the strategy period
January–December 2025 in brief
Net sales amounted to EUR 3,522 thousand (1–12/2024: EUR 4,544 thousand)
Sales margin was EUR 2,314 (3,221) thousand, or 65.7% (70.9%) of net sales
EBITDA was EUR -8,476 (-4,053) thousand
The result for the reporting period amounted to EUR -9,483 (-4,614) thousand
The Board of Directors proposes that no dividend be distributed for the financial period January 1, December 31, 2025
Key figures
EUR 1,000 unless otherwise indicated
7–12/2025
7–12/2024
Change, %
1–12/2025
1–12/2024
Change, %
Net sales
1,448
2,482
-41.7 %
3,522
4,544
-22.5 %
Sales margin
1,006
1,770
-43.1 %
2,314
3,221
-28.1 %
Sales margin, %
69.5 %
71.3 %
65.7 %
70.9 %
EBITDA
-3,919
-2,189
-8,476
-4,053
EBIT
-4,026
-2,281
-8,686
-4,202
Profit / loss for the period
-3,855
-2,730
-9,483
-4,614
R&D expenditure, % of net sales
109.8 %
53.5 %
85.8 %
48.0 %
Equity ratio, %
84.3 %
84.9 %
84.3 %
84.9 %
Cash and cash equivalents
4,126
6,289
-34.4 %
4,126
6,289
-34.4 %
Earnings per share (undiluted)
-0.13
-0.12
-0.31
-0.20
Earnings per share (diluted)
-0.11
-0.10
-0.28
-0.17
Number of shares at the end of theperiod (undiluted)
30,788,092
23,336,858
30,788,092
23,336,858
